Microneedle Array Plus Doxorubicin in Cutaneous Squamous Cell Cancer (cSCC)

This study is testing a new way to deliver chemotherapy directly into skin cancer tumors using a device called a microneedle array — tiny needles that painlessly deliver the drug doxorubicin right into the tumor — for people with a type of skin cancer called cutaneous squamous cell carcinoma (cSCC). **You may be eligible if...** - You have a confirmed skin cancer diagnosis of cSCC (cutaneous squamous cell carcinoma) - Your cancer is Stage I to III and can be surgically removed - Your tumor is at least 5 mm in its longest dimension and smaller than 100 mm - You are reasonably active overall (ECOG performance 0–2) and expected to live at least 12 more months - Your blood counts and kidney function are within acceptable ranges **You may NOT be eligible if...** - You are on other experimental drugs or devices - Your blood counts (neutrophils, platelets) or kidney/liver function are too low - You have another active serious illness Talk to your doctor to see if this trial is right for you.